Human antibodies that bind human TNFα

US8753633B2 · kind B2 · utility

Assignee

• AbbVie Biotechnology Ltd. · BM

Inventors

• Jochen G. Salfeld · North Grafton, US
• Deborah J. Allen · London, GB
• Zehra Kaymakcalan · Westborough, US
• Boris Labkovsky · Framingham, US
• John A. Mankovich · Andover, US
• Brian McGuinness · Cambridge, GB
• Andrew J. Roberts · Cambridge, GB
• Paul Sakorafas · Newton, US
• Hendricus R. J. M. Hoogenboom · Eijsden, NL
• David Schoenhaut · Clifton, US
• Tristan Vaughan · Cambridge, GB
• Michael White · Framingham, US
• Alison J. Wilton · Cambridge, GB

Key dates

• Filing date: Jun 15, 2012
• Grant date: Jun 17, 2014
• Expiry date: Jun 15, 2032

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y10S424/81
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e.g., Kd=10−8 M or less), a slow off rate for hTNFα dissociation (e.g., Koff=10−3 sec−1 or less) and neutralize hTNFα activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNFα and for inhibiting hTNFα activity, e.g., in a human subject suffering from a disorder in which hTNFα activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.